GRDN | Ticker Profile - Titan Protect

GRDN

Guardian Pharmacy Services, Inc.

Healthcare · Medical Care Facilities · NYQ

$40.48

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.5B

Total market value of the company

Trailing P/E

46.57

Expensive — high growth expected

Forward P/E

28.80

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.2%

Year-over-year revenue change

Profit Margin

3.6%

How much profit the company keeps from each dollar of revenue

ROE

26.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$43.00

+6% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.

https://guardianpharmacy.com

Country: United States Employees: 3,600 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.358

Excellent risk-adjusted returns

Kelly Fraction

0.1113

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.589

Returns exceed worst-case losses — strong risk profile

Annual Return

70.5%

Historical annualised return based on price data

Max Drawdown

-27.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$41.36

2% below the year high

52W Low

$19.17

111% above the year low

Avg Volume

480,988

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.5%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.84

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.72

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.47

Adequate but worth monitoring

Quick Ratio

1.10

Like current ratio but excludes inventory — stricter test

Gross Margin

20.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.2%

Profit from core operations before interest and tax

Free Cash Flow

$67M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.5B

Total revenue over the last 12 months

Net Income

$53M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$45.00

Target Median

$43.00

Target Low

$42.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go